Probiotics in the Treatment of Irritable Bowel Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2013

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Probiotic

Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.

DRUG

Placebo

Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.

Trial Locations (1)

81746-73461

Department of Gastroenterology, Alzahra Hospital, Isfahan

All Listed Sponsors
lead

Isfahan University of Medical Sciences

OTHER

NCT01837472 - Probiotics in the Treatment of Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter